Private Advisor Group’s Karyopharm Therapeutics KPTI Stock Holding History

Private Advisor Group’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-738	Closed	-$116K	–	2018
2021 Q1	$116K	Buy	738 +9	+1%	+$1.9K	﹤0.01%	1795
2020 Q4	$169K	Buy	+729	New	+$169K	﹤0.01%	1647
2020 Q3	–	Sell	-23	Closed	-$7K	–	2588
2020 Q2	$7K	Buy	+23	New	+$6.8K	﹤0.01%	3087

Other funds holding KPTI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

DMPV

Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Private Advisor Group's KPTI Position: Q2 2021 in Review

Private Advisor Group sold out of Karyopharm Therapeutics (KPTI) in Q2 2021, closing a stake of 738 shares — an estimated $116K sold.

Private Advisor Group first reported a position in KPTI in Q2 2020 and held it in 3 quarters. The position peaked at $169K in Q4 2020. 153 funds tracked by Wall St. Rank hold KPTI as of Q2 2021.

Private Advisor Group reported no remaining Karyopharm Therapeutics position as of Q2 2021 after selling out during the quarter.
Private Advisor Group sold 738 Karyopharm Therapeutics shares in Q2 2021, an estimated $116K.
Private Advisor Group first reported a position in Karyopharm Therapeutics in Q2 2020 and held it in 3 quarters.
Private Advisor Group's Karyopharm Therapeutics position peaked at $169K in Q4 2020.
153 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2021.

Based on Private Advisor Group's 13F filing for Q2 2021, filed 12 Aug 2021.